Trial Profile
Efficacy and safety of ONO-4538 for chemo-refractory germ cell tumors: an open-label, multicentre, phase 2 trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Germ cell cancer; Seminoma
- Focus Therapeutic Use
- Acronyms NICHE-GCT study
- 01 Jul 2022 Results of a biomarker analysis assessing death ligand-1 expression and genomic sequencing \published in the International Journal of Urology
- 19 Jul 2021 Status changed from active, no longer recruiting to completed.
- 27 Dec 2018 Status changed from recruiting to active, no longer recruiting.